Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Bile Duct Cancer Drug Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Bile Duct Cancer Drug Market Status and Forecast (2016-2027)
      • 1.3.2 Global Bile Duct Cancer Drug Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Bile Duct Cancer Drug Supply by Company

    • 2.1 Global Bile Duct Cancer Drug Sales Volume by Company
    • 2.2 Global Bile Duct Cancer Drug Sales Value by Company
    • 2.3 Global Bile Duct Cancer Drug Price by Company
    • 2.4 Bile Duct Cancer Drug Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Bile Duct Cancer Drug Market Status by Category

    • 3.1 Bile Duct Cancer Drug Category Introduction
      • 3.1.1 Cabozantinib S-malate
      • 3.1.2 Elpamotide
      • 3.1.3 Exatecan Mesylate
      • 3.1.4 LY-2801653
      • 3.1.5 NUC-1031
      • 3.1.6 Others
    • 3.2 Global Bile Duct Cancer Drug Market by Category
      • 3.2.1 Global Bile Duct Cancer Drug Sales Volume by Category (2016-2021)
      • 3.2.2 Global Bile Duct Cancer Drug Sales Value by Category (2016-2021)
      • 3.2.3 Global Bile Duct Cancer Drug Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Bile Duct Cancer Drug Market Status by End User/Segment

    • 4.1 Bile Duct Cancer Drug Segment by End User/Segment
      • 4.1.1 Hospital
      • 4.1.2 Clinic
      • 4.1.3 Others
    • 4.2 Global Bile Duct Cancer Drug Market by End User/Segment
      • 4.2.1 Global Bile Duct Cancer Drug Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Bile Duct Cancer Drug Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Bile Duct Cancer Drug Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Bile Duct Cancer Drug Market Status by Region

    • 5.1 Global Bile Duct Cancer Drug Market by Region
      • 5.1.1 Global Bile Duct Cancer Drug Sales Volume by Region
      • 5.1.2 Global Bile Duct Cancer Drug Sales Value by Region
    • 5.2 North America Bile Duct Cancer Drug Market Status
    • 5.3 Europe Bile Duct Cancer Drug Market Status
    • 5.4 Asia Pacific Bile Duct Cancer Drug Market Status
    • 5.5 Central & South America Bile Duct Cancer Drug Market Status
    • 5.6 Middle East & Africa Bile Duct Cancer Drug Market Status

    6 North America Bile Duct Cancer Drug Market Status

    • 6.1 North America Bile Duct Cancer Drug Market by Country
      • 6.1.1 North America Bile Duct Cancer Drug Sales Volume by Country (2016-2021)
      • 6.1.2 North America Bile Duct Cancer Drug Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Bile Duct Cancer Drug Market Status

    • 7.1 Europe Bile Duct Cancer Drug Market by Country
      • 7.1.1 Europe Bile Duct Cancer Drug Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Bile Duct Cancer Drug Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Bile Duct Cancer Drug Market Status

    • 8.1 Asia Pacific Bile Duct Cancer Drug Market by Country
      • 8.1.1 Asia Pacific Bile Duct Cancer Drug Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Bile Duct Cancer Drug Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Bile Duct Cancer Drug Market Status

    • 9.1 Central & South America Bile Duct Cancer Drug Market by Country
      • 9.1.1 Central & South America Bile Duct Cancer Drug Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Bile Duct Cancer Drug Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Bile Duct Cancer Drug Market Status

    • 10.1 Middle East & Africa Bile Duct Cancer Drug Market by Country
      • 10.1.1 Middle East & Africa Bile Duct Cancer Drug Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Bile Duct Cancer Drug Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Bile Duct Cancer Drug Manufacturing Cost Analysis
    • 11.5 Bile Duct Cancer Drug Sales Channel and Distributors Analysis
      • 11.5.1 Bile Duct Cancer Drug Sales Channel
      • 11.5.2 Bile Duct Cancer Drug Distributors
    • 11.6 Bile Duct Cancer Drug Downstream Major Buyers

    12 Global Bile Duct Cancer Drug Market Forecast by Category and by End User/Segment

    • 12.1 Global Bile Duct Cancer Drug Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Bile Duct Cancer Drug Forecast by Category
      • 12.2.1 Global Bile Duct Cancer Drug Sales Volume Forecast by Category
      • 12.2.2 Global Bile Duct Cancer Drug Sales Value Forecast by Category
      • 12.2.3 Global Bile Duct Cancer Drug Price Forecast by Category
    • 12.3 Global Bile Duct Cancer Drug Forecast by End User/Segment
      • 12.3.1 Global Bile Duct Cancer Drug Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Bile Duct Cancer Drug Sales Value Forecast by End User/Segment
      • 12.3.3 Global Bile Duct Cancer Drug Price Forecast by End User/Segment

    13 Global Bile Duct Cancer Drug Market Forecast by Region/Country

    • 13.1 Global Bile Duct Cancer Drug Market Forecast by Region (2022-2027)
      • 13.1.1 Global Bile Duct Cancer Drug Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Bile Duct Cancer Drug Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Concordia Healthcare Corp.
      • 14.1.1 Company Information
      • 14.1.2 Bile Duct Cancer Drug Product Introduction
      • 14.1.3 Concordia Healthcare Corp. Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Cellular Biomedicine Group, Inc.
      • 14.2.1 Company Information
      • 14.2.2 Bile Duct Cancer Drug Product Introduction
      • 14.2.3 Cellular Biomedicine Group, Inc. Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Cellceutix Corporation
      • 14.3.1 Company Information
      • 14.3.2 Bile Duct Cancer Drug Product Introduction
      • 14.3.3 Cellceutix Corporation Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 CellAct Pharma GmbH
      • 14.4.1 Company Information
      • 14.4.2 Bile Duct Cancer Drug Product Introduction
      • 14.4.3 CellAct Pharma GmbH Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Celgene Corporation
      • 14.5.1 Company Information
      • 14.5.2 Bile Duct Cancer Drug Product Introduction
      • 14.5.3 Celgene Corporation Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Bristol-Myers Squibb Company
      • 14.6.1 Company Information
      • 14.6.2 Bile Duct Cancer Drug Product Introduction
      • 14.6.3 Bristol-Myers Squibb Company Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Boston Biomedical, Inc.
      • 14.7.1 Company Information
      • 14.7.2 Bile Duct Cancer Drug Product Introduction
      • 14.7.3 Boston Biomedical, Inc. Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Boehringer Ingelheim GmbH
      • 14.8.1 Company Information
      • 14.8.2 Bile Duct Cancer Drug Product Introduction
      • 14.8.3 Boehringer Ingelheim GmbH Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Blueprint Medicines Corporation
      • 14.9.1 Company Information
      • 14.9.2 Bile Duct Cancer Drug Product Introduction
      • 14.9.3 Blueprint Medicines Corporation Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Bayer AG
      • 14.10.1 Company Information
      • 14.10.2 Bile Duct Cancer Drug Product Introduction
      • 14.10.3 Bayer AG Bile Duct Cancer Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Bavarian Nordic A/S
    • 14.12 Aslan Pharmaceuticals Pte. Ltd.
    • 14.13 Arrien Pharmaceuticals, LLC
    • 14.14 Array BioPharma Inc.
    • 14.15 ArQule, Inc.
    • 14.16 Ariad Pharmaceuticals, Inc.

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Bile Duct Cancer Drug market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Bile Duct Cancer Drug market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Cabozantinib S-malate
      Elpamotide
      Exatecan Mesylate
      LY-2801653
      NUC-1031
      Others

      Segmented by End User/Segment
      Hospital
      Clinic
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Concordia Healthcare Corp.
      Cellular Biomedicine Group, Inc.
      Cellceutix Corporation
      CellAct Pharma GmbH
      Celgene Corporation
      Bristol-Myers Squibb Company
      Boston Biomedical, Inc.
      Boehringer Ingelheim GmbH
      Blueprint Medicines Corporation
      Bayer AG
      Bavarian Nordic A/S
      Aslan Pharmaceuticals Pte. Ltd.
      Arrien Pharmaceuticals, LLC
      Array BioPharma Inc.
      ArQule, Inc.
      Ariad Pharmaceuticals, Inc.
      Buy now